Xeris Pharmaceuticals, Inc. is a pharmaceutical company. It is a company that engages in developing and commercializing injectable and infusible drug formulations. The company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.
The company's formulation technologies enable the subcutaneous and intramuscular delivery of formulations of peptides, proteins, antibodies and small molecules using commercially available syringes, multi-dose pens, auto-injectors, and infusion pumps.
Xeris is developing its lead product candidate, the Glucagon Rescue Pen, for the purpose of treating severe hypoglycemia in people with diabetes. It is also involved in the development of treatments for post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen provides a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.